| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oncolytic Virotherapy | 38 | 2024 | 239 | 6.390 |
Why?
|
| Glioma | 65 | 2024 | 1986 | 5.020 |
Why?
|
| Oncolytic Viruses | 27 | 2024 | 169 | 4.800 |
Why?
|
| Brain Neoplasms | 50 | 2024 | 4966 | 3.210 |
Why?
|
| Receptor, TIE-2 | 9 | 2017 | 78 | 3.030 |
Why?
|
| Adenoviridae | 47 | 2024 | 1492 | 2.840 |
Why?
|
| Glioblastoma | 21 | 2024 | 1776 | 1.600 |
Why?
|
| E2F1 Transcription Factor | 13 | 2010 | 198 | 1.230 |
Why?
|
| Autophagy | 15 | 2016 | 906 | 0.870 |
Why?
|
| Brain Stem Neoplasms | 5 | 2022 | 100 | 0.830 |
Why?
|
| Adenoviruses, Human | 9 | 2011 | 191 | 0.820 |
Why?
|
| Tumor Microenvironment | 12 | 2024 | 3041 | 0.740 |
Why?
|
| Genetic Therapy | 15 | 2012 | 1715 | 0.740 |
Why?
|
| Adenovirus E1A Proteins | 8 | 2007 | 165 | 0.720 |
Why?
|
| Angiopoietin-2 | 3 | 2016 | 36 | 0.690 |
Why?
|
| Cell Line, Tumor | 38 | 2024 | 14873 | 0.670 |
Why?
|
| Mesothelioma | 1 | 2024 | 558 | 0.630 |
Why?
|
| Adenovirus E1B Proteins | 4 | 2011 | 20 | 0.630 |
Why?
|
| Syk Kinase | 1 | 2018 | 65 | 0.610 |
Why?
|
| Animals | 64 | 2024 | 61554 | 0.600 |
Why?
|
| Caveolae | 1 | 2017 | 21 | 0.590 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2016 | 1270 | 0.590 |
Why?
|
| Monocytes | 3 | 2016 | 784 | 0.540 |
Why?
|
| Caveolin 1 | 1 | 2017 | 201 | 0.540 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2016 | 84 | 0.520 |
Why?
|
| Neoplastic Stem Cells | 9 | 2016 | 1456 | 0.490 |
Why?
|
| Gene Expression Regulation, Neoplastic | 16 | 2017 | 9044 | 0.490 |
Why?
|
| DNA-Binding Proteins | 9 | 2006 | 4994 | 0.490 |
Why?
|
| Tyrosine | 1 | 2016 | 503 | 0.470 |
Why?
|
| Adenoviridae Infections | 5 | 2023 | 114 | 0.470 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2014 | 1580 | 0.470 |
Why?
|
| Mice, Nude | 19 | 2021 | 4331 | 0.460 |
Why?
|
| Oligopeptides | 7 | 2024 | 450 | 0.460 |
Why?
|
| Dacarbazine | 5 | 2016 | 502 | 0.460 |
Why?
|
| Mice | 40 | 2024 | 35477 | 0.430 |
Why?
|
| Genetic Vectors | 16 | 2019 | 1847 | 0.430 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2024 | 3924 | 0.430 |
Why?
|
| Neoplasms | 9 | 2024 | 15933 | 0.430 |
Why?
|
| Humans | 117 | 2024 | 271093 | 0.430 |
Why?
|
| Neovascularization, Pathologic | 6 | 2008 | 1586 | 0.420 |
Why?
|
| Telomerase | 2 | 2006 | 544 | 0.410 |
Why?
|
| Drug Resistance, Multiple | 2 | 2013 | 221 | 0.410 |
Why?
|
| Cell Nucleus | 1 | 2017 | 1715 | 0.400 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2013 | 317 | 0.380 |
Why?
|
| DNA Damage | 4 | 2019 | 1990 | 0.380 |
Why?
|
| Oxygen | 2 | 2014 | 789 | 0.380 |
Why?
|
| Virus Replication | 15 | 2024 | 783 | 0.380 |
Why?
|
| Cell Cycle Proteins | 7 | 2002 | 2112 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 10400 | 0.360 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 1942 | 0.360 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2016 | 5417 | 0.360 |
Why?
|
| Retinoblastoma Protein | 9 | 2010 | 339 | 0.340 |
Why?
|
| Endothelial Cells | 3 | 2016 | 1032 | 0.320 |
Why?
|
| Histones | 1 | 2016 | 1512 | 0.310 |
Why?
|
| Macrophages | 1 | 2015 | 1333 | 0.310 |
Why?
|
| Tumor Cells, Cultured | 20 | 2024 | 5759 | 0.310 |
Why?
|
| Antigens, Neoplasm | 5 | 2024 | 1581 | 0.310 |
Why?
|
| Apoptosis | 13 | 2020 | 7755 | 0.310 |
Why?
|
| Inflammation | 1 | 2018 | 2492 | 0.300 |
Why?
|
| Cell Adhesion | 2 | 2010 | 1023 | 0.300 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2007 | 396 | 0.290 |
Why?
|
| Neovascularization, Physiologic | 2 | 2011 | 341 | 0.280 |
Why?
|
| Immunity, Innate | 3 | 2024 | 697 | 0.280 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2011 | 1630 | 0.280 |
Why?
|
| Camptothecin | 2 | 2009 | 540 | 0.280 |
Why?
|
| Pyrans | 2 | 2016 | 13 | 0.270 |
Why?
|
| Gene Transfer Techniques | 8 | 2015 | 800 | 0.260 |
Why?
|
| Antineoplastic Agents, Alkylating | 5 | 2016 | 605 | 0.260 |
Why?
|
| Integrin beta1 | 1 | 2006 | 127 | 0.260 |
Why?
|
| Promoter Regions, Genetic | 8 | 2013 | 3204 | 0.260 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2006 | 58 | 0.260 |
Why?
|
| Immunotherapy | 4 | 2024 | 3559 | 0.250 |
Why?
|
| Biological Therapy | 2 | 2010 | 57 | 0.250 |
Why?
|
| Protein Transport | 3 | 2017 | 737 | 0.250 |
Why?
|
| Defective Viruses | 1 | 2004 | 38 | 0.240 |
Why?
|
| Neuroglia | 1 | 2006 | 251 | 0.240 |
Why?
|
| Transcription Factors | 9 | 2003 | 5416 | 0.240 |
Why?
|
| Phosphoric Monoester Hydrolases | 5 | 2003 | 264 | 0.230 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2020 | 205 | 0.230 |
Why?
|
| Marriage | 1 | 2024 | 50 | 0.230 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 523 | 0.230 |
Why?
|
| Genetic Linkage | 1 | 2005 | 603 | 0.230 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2016 | 1900 | 0.220 |
Why?
|
| Cancer Vaccines | 2 | 2020 | 754 | 0.220 |
Why?
|
| Biological Assay | 2 | 2016 | 176 | 0.210 |
Why?
|
| Melanoma, Experimental | 4 | 2019 | 382 | 0.210 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 4900 | 0.210 |
Why?
|
| Osteosarcoma | 3 | 2022 | 951 | 0.200 |
Why?
|
| Up-Regulation | 4 | 2017 | 2414 | 0.200 |
Why?
|
| Cell Survival | 11 | 2019 | 3058 | 0.200 |
Why?
|
| Melanoma | 1 | 2019 | 5597 | 0.200 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 3 | 2017 | 172 | 0.190 |
Why?
|
| Flow Cytometry | 7 | 2014 | 3042 | 0.190 |
Why?
|
| Carrier Proteins | 6 | 1999 | 2085 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 898 | 0.190 |
Why?
|
| Phosphorylation | 4 | 2018 | 4906 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2011 | 1544 | 0.180 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 85 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2005 | 3657 | 0.180 |
Why?
|
| Transplantation, Heterologous | 8 | 2007 | 1053 | 0.180 |
Why?
|
| Blotting, Western | 7 | 2011 | 3570 | 0.180 |
Why?
|
| E2F Transcription Factors | 7 | 2002 | 136 | 0.180 |
Why?
|
| Immunomodulation | 2 | 2019 | 253 | 0.180 |
Why?
|
| Transfection | 6 | 2009 | 3110 | 0.180 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2020 | 98 | 0.170 |
Why?
|
| Rhabdoid Tumor | 1 | 2020 | 106 | 0.170 |
Why?
|
| Cyclins | 2 | 2001 | 465 | 0.170 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2014 | 284 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2020 | 551 | 0.160 |
Why?
|
| Immunity | 1 | 2021 | 353 | 0.160 |
Why?
|
| Teratoma | 1 | 2020 | 248 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 7 | 2023 | 7054 | 0.150 |
Why?
|
| Genes, p53 | 5 | 2001 | 1140 | 0.150 |
Why?
|
| Adaptive Immunity | 2 | 2021 | 151 | 0.150 |
Why?
|
| Gene Expression Regulation, Viral | 4 | 2007 | 197 | 0.150 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2016 | 202 | 0.150 |
Why?
|
| Models, Biological | 5 | 2015 | 3189 | 0.150 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 1107 | 0.140 |
Why?
|
| Protein Binding | 3 | 2016 | 3473 | 0.140 |
Why?
|
| HeLa Cells | 2 | 2017 | 1684 | 0.140 |
Why?
|
| Antineoplastic Agents | 7 | 2018 | 14636 | 0.140 |
Why?
|
| Cell Cycle | 8 | 2008 | 2135 | 0.140 |
Why?
|
| Combined Modality Therapy | 7 | 2024 | 9039 | 0.140 |
Why?
|
| E2F2 Transcription Factor | 3 | 2008 | 27 | 0.140 |
Why?
|
| B7-H1 Antigen | 2 | 2021 | 1089 | 0.140 |
Why?
|
| HEK293 Cells | 2 | 2017 | 1459 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 4 | 2014 | 4052 | 0.130 |
Why?
|
| Neoplasm Proteins | 4 | 2013 | 3345 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 589 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 7 | 1999 | 1127 | 0.130 |
Why?
|
| Angiotensin I | 1 | 2016 | 16 | 0.130 |
Why?
|
| Viruses | 3 | 2008 | 156 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 7 | 2001 | 506 | 0.130 |
Why?
|
| Cell Self Renewal | 1 | 2016 | 69 | 0.130 |
Why?
|
| Spheroids, Cellular | 2 | 2015 | 220 | 0.130 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2016 | 157 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 972 | 0.130 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 2 | 1993 | 13 | 0.130 |
Why?
|
| Capsid | 1 | 2016 | 178 | 0.130 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 690 | 0.130 |
Why?
|
| DNA End-Joining Repair | 1 | 2016 | 92 | 0.130 |
Why?
|
| Radiation, Ionizing | 1 | 2016 | 190 | 0.120 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2015 | 305 | 0.120 |
Why?
|
| Species Specificity | 2 | 2008 | 790 | 0.120 |
Why?
|
| Paraneoplastic Syndromes | 2 | 1993 | 82 | 0.120 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1725 | 0.120 |
Why?
|
| Sarcoma | 1 | 2005 | 1851 | 0.120 |
Why?
|
| Cisplatin | 2 | 2014 | 2499 | 0.120 |
Why?
|
| Mice, Transgenic | 3 | 2015 | 4202 | 0.120 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 7320 | 0.120 |
Why?
|
| fas Receptor | 1 | 2015 | 197 | 0.110 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 2189 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 1123 | 0.110 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 271 | 0.110 |
Why?
|
| Encephalomyelitis | 2 | 1993 | 8 | 0.110 |
Why?
|
| Sirolimus | 2 | 2008 | 830 | 0.110 |
Why?
|
| Melatonin | 1 | 2013 | 53 | 0.110 |
Why?
|
| Child | 6 | 2024 | 30596 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 349 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 3587 | 0.100 |
Why?
|
| Stromal Cells | 1 | 2016 | 823 | 0.100 |
Why?
|
| Radiation Tolerance | 1 | 2016 | 639 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 2 | 1993 | 426 | 0.100 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2024 | 174 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2013 | 2770 | 0.100 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 2011 | 22 | 0.100 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 660 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 1003 | 0.090 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2011 | 119 | 0.090 |
Why?
|
| Research Design | 1 | 2018 | 1570 | 0.090 |
Why?
|
| Wernicke Encephalopathy | 1 | 1990 | 12 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 1523 | 0.090 |
Why?
|
| Immunoblotting | 3 | 2009 | 888 | 0.090 |
Why?
|
| Abducens Nerve | 1 | 1990 | 8 | 0.090 |
Why?
|
| Immunohistochemistry | 6 | 2014 | 7645 | 0.090 |
Why?
|
| Gene Targeting | 1 | 2012 | 312 | 0.090 |
Why?
|
| DNA, Neoplasm | 3 | 2011 | 1958 | 0.090 |
Why?
|
| Heroin | 1 | 1990 | 23 | 0.090 |
Why?
|
| Down-Regulation | 4 | 2016 | 2087 | 0.090 |
Why?
|
| Bevacizumab | 1 | 2014 | 967 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2003 | 667 | 0.090 |
Why?
|
| Epigenomics | 1 | 2011 | 272 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 266 | 0.090 |
Why?
|
| Ophthalmoplegia | 1 | 1990 | 60 | 0.090 |
Why?
|
| Chickens | 2 | 2011 | 783 | 0.090 |
Why?
|
| Endothelial Growth Factors | 2 | 2001 | 231 | 0.080 |
Why?
|
| Cell Death | 3 | 2014 | 686 | 0.080 |
Why?
|
| Cell Division | 5 | 2003 | 2657 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2011 | 1704 | 0.080 |
Why?
|
| Phenotype | 4 | 2016 | 6503 | 0.080 |
Why?
|
| Lymphokines | 2 | 2001 | 313 | 0.080 |
Why?
|
| Genes, p16 | 2 | 2007 | 132 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 2674 | 0.080 |
Why?
|
| Mitoxantrone | 1 | 2009 | 227 | 0.080 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2009 | 85 | 0.080 |
Why?
|
| Astrocytoma | 2 | 2022 | 325 | 0.080 |
Why?
|
| Gene Silencing | 2 | 2011 | 825 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 622 | 0.080 |
Why?
|
| Neurology | 1 | 2010 | 120 | 0.080 |
Why?
|
| Kinetics | 2 | 2006 | 2210 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2009 | 5056 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2003 | 2617 | 0.080 |
Why?
|
| Caspases | 1 | 2011 | 672 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1990 | 368 | 0.080 |
Why?
|
| Substance-Related Disorders | 2 | 1990 | 547 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2001 | 537 | 0.080 |
Why?
|
| Cell Communication | 1 | 2010 | 509 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 3416 | 0.070 |
Why?
|
| Cell Line | 5 | 2015 | 5326 | 0.070 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2007 | 72 | 0.070 |
Why?
|
| Oncogenes | 2 | 2008 | 698 | 0.070 |
Why?
|
| Genes, Viral | 2 | 2006 | 257 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2013 | 1355 | 0.070 |
Why?
|
| S Phase | 2 | 2006 | 288 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2011 | 1801 | 0.070 |
Why?
|
| Genes, Retinoblastoma | 3 | 2008 | 92 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2003 | 1008 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2022 | 1658 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 361 | 0.070 |
Why?
|
| HIV-1 | 1 | 1990 | 638 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 4 | 2012 | 526 | 0.070 |
Why?
|
| Stem Cells | 2 | 2024 | 1213 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 317 | 0.060 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2006 | 73 | 0.060 |
Why?
|
| Microcirculation | 1 | 2006 | 189 | 0.060 |
Why?
|
| Karyopherins | 1 | 2006 | 134 | 0.060 |
Why?
|
| Gene Expression | 3 | 2006 | 3606 | 0.060 |
Why?
|
| Autophagy-Related Protein 5 | 3 | 2012 | 40 | 0.060 |
Why?
|
| Cytosine Deaminase | 1 | 2005 | 43 | 0.060 |
Why?
|
| Gene Deletion | 3 | 2006 | 1471 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2008 | 496 | 0.060 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 3 | 1999 | 55 | 0.060 |
Why?
|
| Transcription Factor DP1 | 3 | 1999 | 57 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2021 | 33808 | 0.060 |
Why?
|
| DNA Primers | 2 | 2005 | 1492 | 0.060 |
Why?
|
| Ligands | 1 | 2007 | 1008 | 0.060 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2004 | 38 | 0.060 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2004 | 40 | 0.060 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2005 | 506 | 0.060 |
Why?
|
| Restriction Mapping | 1 | 2004 | 329 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2004 | 153 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 3472 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2008 | 1161 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2010 | 5662 | 0.060 |
Why?
|
| Mutation | 7 | 2010 | 15904 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2004 | 239 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 1552 | 0.050 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2003 | 142 | 0.050 |
Why?
|
| Infusions, Intralesional | 1 | 2022 | 6 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2006 | 881 | 0.050 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2016 | 236 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 3533 | 0.050 |
Why?
|
| Cranial Irradiation | 1 | 2004 | 321 | 0.050 |
Why?
|
| Rabbits | 1 | 2024 | 1045 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2006 | 616 | 0.050 |
Why?
|
| Base Sequence | 3 | 2005 | 5417 | 0.050 |
Why?
|
| Kynurenine | 1 | 2022 | 67 | 0.050 |
Why?
|
| Injections, Intralesional | 2 | 2018 | 169 | 0.050 |
Why?
|
| DNA Repair | 2 | 2007 | 1906 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 273 | 0.050 |
Why?
|
| Lung Neoplasms | 5 | 2017 | 12040 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2019 | 1572 | 0.050 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2022 | 67 | 0.050 |
Why?
|
| MicroRNAs | 2 | 2016 | 2882 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2010 | 1463 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2003 | 229 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2009 | 3146 | 0.050 |
Why?
|
| E2F4 Transcription Factor | 1 | 2001 | 30 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 862 | 0.050 |
Why?
|
| Mesocricetus | 1 | 2021 | 116 | 0.050 |
Why?
|
| Eye Proteins | 1 | 2003 | 275 | 0.050 |
Why?
|
| Survival Rate | 3 | 2018 | 12535 | 0.050 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2001 | 21 | 0.050 |
Why?
|
| Binding Sites | 2 | 2006 | 2249 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2003 | 294 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2003 | 344 | 0.050 |
Why?
|
| Carmustine | 1 | 2001 | 225 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2001 | 172 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2011 | 2923 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 381 | 0.050 |
Why?
|
| Biomarkers, Tumor | 5 | 2012 | 10714 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2003 | 542 | 0.050 |
Why?
|
| Cricetinae | 1 | 2021 | 762 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2022 | 251 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2005 | 1990 | 0.040 |
Why?
|
| Signal Transduction | 4 | 2016 | 12044 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2001 | 256 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 3846 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 518 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2008 | 2375 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2007 | 2453 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2022 | 381 | 0.040 |
Why?
|
| DNA, Antisense | 1 | 1999 | 44 | 0.040 |
Why?
|
| Dogs | 1 | 2020 | 1074 | 0.040 |
Why?
|
| Medulloblastoma | 1 | 2004 | 569 | 0.040 |
Why?
|
| Female | 10 | 2020 | 149120 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 437 | 0.040 |
Why?
|
| Exons | 2 | 2008 | 1390 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 303 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2001 | 755 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 738 | 0.040 |
Why?
|
| Forecasting | 1 | 2001 | 702 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2023 | 1020 | 0.040 |
Why?
|
| Models, Animal | 1 | 2020 | 653 | 0.040 |
Why?
|
| Synapses | 1 | 2022 | 541 | 0.040 |
Why?
|
| Gelatinases | 1 | 1997 | 53 | 0.040 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 16238 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2005 | 6343 | 0.040 |
Why?
|
| OX40 Ligand | 1 | 2017 | 23 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 319 | 0.040 |
Why?
|
| Topotecan | 1 | 1998 | 248 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 1301 | 0.040 |
Why?
|
| A549 Cells | 1 | 2017 | 127 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 1997 | 171 | 0.040 |
Why?
|
| Dinucleoside Phosphates | 1 | 1996 | 25 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 4966 | 0.030 |
Why?
|
| Necrosis | 2 | 2016 | 593 | 0.030 |
Why?
|
| Pyridones | 1 | 2019 | 364 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2019 | 1699 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 3330 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2016 | 126 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2016 | 111 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2016 | 88 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1995 | 275 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2016 | 125 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 1582 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2003 | 2050 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2016 | 176 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2016 | 286 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2016 | 219 | 0.030 |
Why?
|
| Everolimus | 2 | 2008 | 436 | 0.030 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2016 | 116 | 0.030 |
Why?
|
| Hydrogels | 1 | 2015 | 134 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 238 | 0.030 |
Why?
|
| Adipocytes | 1 | 2016 | 295 | 0.030 |
Why?
|
| Hybridomas | 1 | 2014 | 70 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1824 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2020 | 7232 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 2990 | 0.030 |
Why?
|
| Epitopes | 1 | 2016 | 705 | 0.030 |
Why?
|
| Exosomes | 1 | 2016 | 255 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2021 | 2440 | 0.030 |
Why?
|
| Homozygote | 1 | 1996 | 772 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 573 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 5165 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2008 | 6655 | 0.030 |
Why?
|
| Biopsy | 2 | 2018 | 3488 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 1992 | 50 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2011 | 88 | 0.020 |
Why?
|
| Chorioallantoic Membrane | 1 | 2011 | 25 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 654 | 0.020 |
Why?
|
| Bezafibrate | 1 | 1991 | 7 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 497 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2011 | 220 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2008 | 4542 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 121 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2010 | 24 | 0.020 |
Why?
|
| Astrocytes | 2 | 2005 | 406 | 0.020 |
Why?
|
| Paclitaxel | 1 | 1998 | 2105 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 1991 | 157 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2001 | 246 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 3435 | 0.020 |
Why?
|
| Drug Overdose | 1 | 1990 | 97 | 0.020 |
Why?
|
| Cranial Nerve Diseases | 1 | 1990 | 77 | 0.020 |
Why?
|
| Central Nervous System | 1 | 1992 | 452 | 0.020 |
Why?
|
| Mitochondria | 1 | 2016 | 1292 | 0.020 |
Why?
|
| CpG Islands | 1 | 2011 | 669 | 0.020 |
Why?
|
| Vacuoles | 1 | 2009 | 48 | 0.020 |
Why?
|
| Neural Stem Cells | 1 | 2010 | 182 | 0.020 |
Why?
|
| Cocaine | 1 | 1990 | 242 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2012 | 624 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2011 | 765 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 104 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2010 | 389 | 0.020 |
Why?
|
| Adolescent | 2 | 2022 | 32784 | 0.020 |
Why?
|
| Male | 5 | 2020 | 128484 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 4794 | 0.020 |
Why?
|
| Phagosomes | 1 | 2007 | 72 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1197 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 7900 | 0.020 |
Why?
|
| Prognosis | 1 | 2005 | 22529 | 0.020 |
Why?
|
| Aorta | 1 | 2011 | 666 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1190 | 0.020 |
Why?
|
| Brain | 2 | 2013 | 4205 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 1526 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 662 | 0.020 |
Why?
|
| Tropism | 1 | 2006 | 18 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 13445 | 0.020 |
Why?
|
| Herpesviridae | 1 | 2006 | 43 | 0.020 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2010 | 522 | 0.020 |
Why?
|
| Time Factors | 2 | 1998 | 12991 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2022 | 17095 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2008 | 908 | 0.020 |
Why?
|
| Flucytosine | 1 | 2005 | 33 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 1 | 2005 | 69 | 0.020 |
Why?
|
| Purines | 1 | 2006 | 271 | 0.020 |
Why?
|
| Azacitidine | 1 | 2011 | 1218 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 5054 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2016 | 9290 | 0.010 |
Why?
|
| Luciferases | 1 | 2005 | 454 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 2 | 2000 | 2428 | 0.010 |
Why?
|
| Cell Movement | 1 | 2011 | 2468 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2007 | 784 | 0.010 |
Why?
|
| Hippocalcin | 1 | 2003 | 13 | 0.010 |
Why?
|
| Trypan Blue | 1 | 2003 | 15 | 0.010 |
Why?
|
| Recoverin | 1 | 2003 | 19 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 1417 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2008 | 1306 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2003 | 232 | 0.010 |
Why?
|
| Adult | 3 | 2018 | 82174 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2002 | 374 | 0.010 |
Why?
|
| Integrins | 1 | 2003 | 274 | 0.010 |
Why?
|
| Retinoblastoma | 1 | 2003 | 189 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1990 | 4838 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2005 | 656 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2003 | 464 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 16720 | 0.010 |
Why?
|
| Helper Viruses | 1 | 1999 | 64 | 0.010 |
Why?
|
| Multigene Family | 1 | 2001 | 469 | 0.010 |
Why?
|
| Middle Aged | 3 | 2018 | 90524 | 0.010 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 1998 | 48 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1998 | 142 | 0.010 |
Why?
|
| Actins | 1 | 2001 | 586 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 2179 | 0.010 |
Why?
|
| Prodrugs | 1 | 1999 | 226 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1997 | 273 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2001 | 525 | 0.010 |
Why?
|
| Laminin | 1 | 1997 | 208 | 0.010 |
Why?
|
| G1 Phase | 1 | 1998 | 305 | 0.010 |
Why?
|
| Proteoglycans | 1 | 1997 | 278 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 1997 | 258 | 0.010 |
Why?
|
| Syndrome | 1 | 1999 | 1409 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1997 | 632 | 0.010 |
Why?
|
| Codon | 1 | 1995 | 261 | 0.010 |
Why?
|
| Methylation | 1 | 1996 | 625 | 0.010 |
Why?
|
| Collagen | 1 | 1997 | 723 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2009 | 4796 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 4826 | 0.010 |
Why?
|
| Sensation Disorders | 1 | 1993 | 38 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1997 | 2142 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1995 | 1247 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1997 | 1403 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1995 | 1273 | 0.010 |
Why?
|
| Muscles | 1 | 1991 | 443 | 0.010 |
Why?
|
| Aged | 2 | 1993 | 73550 | 0.010 |
Why?
|
| Alleles | 1 | 1995 | 2597 | 0.010 |
Why?
|
| Rats | 1 | 1997 | 6404 | 0.000 |
Why?
|
| Genotype | 1 | 1995 | 4249 | 0.000 |
Why?
|
| Disease Progression | 1 | 1998 | 6868 | 0.000 |
Why?
|